Skip to main content
SpringerLink
Log in

The Design and Synthesis of Prodrugs for Antibody-Directed Enzyme Prodrug Therapy (ADEPT)

  • Chapter
Enzyme-Prodrug Strategies for Cancer Therapy

Abstract

Antibody-directed enzyme prodrug therapy (ADEPT) is a strategy for treating cancer that combines antibody specificity with enzymatic catalysis to deliver drugs selectively to tumor sites. In this approach a conjugate consisting of an enzyme chemically linked to a tumor-selective antibody (mAb) is administered to the host and allowed to localize at the tumor site. After a suitable interval to allow clearance of the conjugate from the blood, a non-toxic prodrug is administered which releases a therapeutic drug on contact with the enzyme. This two-step approach has the potential to overcome many of the limitations of current chemotherapeutic strategies, allow the generation of high intratumoral concentrations of drug, and minimize damage to normal tissues.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Atwell, G. J., Boyd, M., Palmer, B. D., Anderson, R. F, Pullen, S. M., Wilson, W. R., and Denny, W. A., 1996, Synthesis and evaluation of 4-substituted analogues of 5-[N-N-bis(2-chloroethyl)amino]-2-nitrobenzamide as bioreductively activated prodrugs using an Escherichia coli nitroreductase, Anticancer Drug Des. 11:553–567.

    PubMed  CAS  Google Scholar 

  • Azoulay, M., Florent, J-C., Monneret, C., Gesson, J. P., Jacquesy, J-C., Tillequin, F, Koch, M., Bosslet, K., Czech, J., and Hoffman, D., 1995, Prodrugs of anthracycline antibiotics suited for tumour-specific activation, Anticancer Drug Des. 10:441–450.

    PubMed  CAS  Google Scholar 

  • Bagshawe, K. D., 1987, Antibody directed enzymes revive anti-cancer prodrugs concept, Br. J. Cancer 56:531–532.

    Article  PubMed  CAS  Google Scholar 

  • Bagshawe, K. D., Springer, C. J., Searle, F., Antoniw, P., Sharma, S. K., Melton, R. G., and Sherwood, R. F., 1988, A cytotoxic agent can be generated selectively at cancer sites, Br. J. Cancer 58: 700–703.

    Article  PubMed  CAS  Google Scholar 

  • Bagshawe, K. D., Sharma, S. K., Springer, C. J., and Antoniw, P., 1995, Antibody-directed enzyme prodrug therapy: A pilot scale clinical trial, Tumor Targeting 1:17–29.

    Google Scholar 

  • Blakey, D. C., Valcaccia, B. E., East, S., Wright, A. E, Boyle, F. T., Springer, C. J., Burke, P. J., Melton, R. G., and Bagshawe, K. D., 1993, Antitumour effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug, Cell Biophys. 222:1–8.

    Google Scholar 

  • Blakey, D. C., Davies, D. H., Dowell, R. I., East, S. J., Burke, P. J., Sharma, S. K., Springer, C. J., Mauger, A. B., and Melton, R. G., 1995, Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs, Br. J. Cancer 72:1083–1088.

    Article  PubMed  CAS  Google Scholar 

  • Blakey, D. C., Burke, P. J., Davies, D. H., Dowell, R. I., East, S. J., Eckersley, K. P., Fitton, J. E., McDaid, J., Melton, R. G., Niculescu-Duvaz, I. A., Pinder, P. E., Sharma, S. K., Wright, A. F., and Springer, C. J., 1996, ZD2767, an improved system for antibody-directed enzyme prodrug therapy which results in tumour regressions in colorectal tumour xenografts, Cancer Res. 56:3287–3292.

    PubMed  CAS  Google Scholar 

  • Bosslet, K., Czech, J., and Hoffmann, D., 1994, Tumour selective prodrug activation by fusion protein-mediated catalysis, Cancer Res. 54:2151–2159.

    PubMed  CAS  Google Scholar 

  • Bukhari, M. A., Everett, J. L., and Ross, W. C. J., 1972, Aryl-2-halogenoalkylamines. XXVI. Glucuronic, sulphuric and phosphoric esters of p-di-2-chloroethylaminophenol, Biochem. Pharmacol. 21:963–967.

    Article  PubMed  CAS  Google Scholar 

  • Dowell, R., Springer, C. J., Davies, D. H., Hadley, E. M., Burke, P. J., Boyle, E T., Melton, R. G., Connors, T. A., Blakey, D. C., and Mauger, A. B., 1996, New mustard prodrugs for antibody-directed enzyme prodrug therapy (ADEPT): Alternative to the amide link, J. Med. Chem. 39: 1100–1105.

    Article  PubMed  CAS  Google Scholar 

  • Gesson, J.-P., Jacquesy, J.-C., Mondon, M., Petit, P., Renoux, B., Andrianomenjanahary, S., DufatTrinh Van, H., Koch, M., Michel, S., Tillequin, F., Florent, J.-C., Monneret, C., Bosslet, K., Czech, J., and Hoffmann, D., 1994, Prodrugs of anthracyclines for chemotherapy via enzyme-monoclonal antibody conjugates, Anticancer Drug Des. 9:409–423.

    PubMed  CAS  Google Scholar 

  • Haenseler, E., Esswein, A., Vitols, K. S., Montejano, Y., Mueller, B. M., Reisfeld, R. A., and Huennekens, E M., 1992, Activation of methotrexate-a-alanine by carboxypeptidase A monoclonal antibody conjugate, Biochemistry 31:891–897.

    Article  PubMed  CAS  Google Scholar 

  • Hanessian, S., and Wang, J., 1993, Design and synthesis of a cephalosporin-carboplatinum prodrug activatable by a 3-lactamase, Can. J. Chem. 71:896–906.

    Article  CAS  Google Scholar 

  • Hay, M. P., Wilson, W. R., and Denny, W. A., 1995, A novel enediyne prodrug for antibody-directed enzyme prodrug therapy (ADEPT) using E. coli B nitroreductase, Bioorg. Med. Chem. Lett. 5:2829–2834.

    Article  CAS  Google Scholar 

  • Houba, P. H. J., Leenders, R. G. G., Boven, E., Scheeren, J. W., Pinedo, H. M., and Haisma, H. J., 1996, Characterisation of novel anthracycline prodrugs activated by human 3-glucuronudase for use in antibody-directed enzyme prodrug therapy, Biochem. Pharm. 52:455–463.

    Article  PubMed  CAS  Google Scholar 

  • Hudyma, T. W., Bush, K., Colson, K. L., Firestone, R. A., and King, H. D. (1993). Synthesis and release of doxorubicin from a cephalosporin based prodrug by a 3-lactamase-immunoconjugate. Bioorg. Med. Chem. Lett. 3:323–328.

    Article  CAS  Google Scholar 

  • Jungheim, L. N., Shepherd, T. A., and Meyer, D. L., 1992, Synthesis of acylhydrazido-substituted cephems. Design of cephalosporin-vinca alkaloid prodrugs: Substrates for an antibody-targeted enzyme, J. Org. Chem. 57:2334–2340.

    Article  CAS  Google Scholar 

  • Jungheim, L. N., Shepherd, T. A., and Kling, J. K., 1993, Synthesis of a cephalosporin-doxorubicin antitumour prodrug: A substrate for an antibody-targeted enzyme, Heterocycles 35:339–348.

    Article  CAS  Google Scholar 

  • Kerr, D. A., Senter, P. D., Burnett, W. V., Hirschberg, D. L., Hellstrom, I., and Hellstrom, K., 1990, Antibody-penicillin-V-amidase conjugates kill antigen positive cells when combined with doxorubicin phenoxyacetamide, Cancer Immunol. Immunother. 31:202–205.

    Article  PubMed  CAS  Google Scholar 

  • Kerr, D. E., Schreiber, G. J., Vrudhula, V. M., Svensson, H. P., Hellstrom, I., Hellstrom, K. E., and Senter, P. D., 1995, Regressions and cures of melanoma xenografts following treatment with monoclonal antibody 3-lactamase conjugates in combination with anticancer prodrugs, Cancer Res. 55:3558–3563.

    PubMed  CAS  Google Scholar 

  • Knox, R. J., Friedlos, F., and Boland, M. P., 1993, The bioactivation of CB1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy, Cancer Metastasis Rev. 122:195–212.

    Article  Google Scholar 

  • Lee, M., Simpson, J. E., Woo, S., Kaenzig, C., Anlezark, G. M., Eno-Amooquaye, E., and Burke, P. J., 1997. Synthesis of an aminopropyl analog of the experimental anticancer drug tallimustine, and activation of its 4-nitrobenzylcarbamoyl prodrug by nitroreductase and NADH, Bioorg. Medicinal Chem. Lett. 7:1065–1070.

    Article  CAS  Google Scholar 

  • Manger, A. B., Burke, P. J., Somani, H. H., Friedlos F., and Knox, R. J., 1994, Self-immolative prodrugs: Candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme, J. Med. Chem. 37:3452–3458.

    Article  Google Scholar 

  • Meyer, D. L., Jungheim, L. N., Mikolajczyk, S. D., Shepherd, T. A., Starling, J. J., and Ahlem, C. N., 1992, Bioconjugate Chem. 3:42–47.

    Article  CAS  Google Scholar 

  • Meyer, D. L., Jungheim, L. N., Law, K. L., Mikolajczyk, S. D., Shepherd, T. A., Mackensen, D. G., Briggs, S. L., and Starling, J. J., 1993, Site-specific prodrug activation by antibody-ß-lactamase conjugates: Regression and long-term growth inhibition of human colon carcinoma xenograft models, Cancer Res. 53:3956–3963.

    PubMed  CAS  Google Scholar 

  • Rodrigues, M. L., Carter, C., Wirth, C., Mullins, S., Lee, A., and Blackburn, B. K., 1995, Synthesis and 3-lactamase-mediated activation of a cephalosporin-taxol prodrug, Chem. Biol. 2:223–227.

    Article  PubMed  CAS  Google Scholar 

  • Roffler, S. R., Wang, S. M., Chem, J. W., Yeh, M. Y., and Tung, E., 1991, Anti-neoplastic glucuronide prodrug treatment of human tumour cells targeted with a monoclonal antibody-enzyme conjugate, Biochem. Pharmacol. 42:2062–2065.

    Article  PubMed  CAS  Google Scholar 

  • Schmidt, F., Florent, J-C., Monneret, C., Straub, R., Czech, J., Gerken, M., and Bosslet, K., 1997, Glucuronide prodrugs of hydroxy compounds for antibody directed enzyme prodrug therapy (ADEPT): A phenol nitrogen mustard carbamate, Bioorg. Medicinal Chem. Lett. 7:1071–1076.

    Article  CAS  Google Scholar 

  • Senter, P. D., Schreiber, J. G., Hirschberg, D. L., Ashe, S. A., Hellstrom, K. E., and Hellstrom, I., 1989, Enhancement of the in vitro and in vivo antitumour activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates, Cancer Res. 49:5789–5792.

    PubMed  CAS  Google Scholar 

  • Senter, P. D.,1990, Activation of prodrugs by antibody-enzyme conjugates: A new approach to cancer therapy, FASEB J. 4:188–193.

    PubMed  CAS  Google Scholar 

  • Senter, P. D., Su, P. C. D., Katsuragi, T., Sakai, T., Cosland, W. L., Hellstrom, I., and Hellstrom, K. E., 1991, Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates, Bioconjugate Chem. 2:447–451.

    Article  CAS  Google Scholar 

  • Shepherd, T. A., Jungheim, L. N., Meyer, D. L., and Starling, J. (1991). A novel targeted delivery system using a cephalosporin-oncolytic prodrug activated by an antibody- 3-lactamase conjugate for the treatment of cancer. Bioorg. Med. Chem. Lett.,1:21–26.

    Article  CAS  Google Scholar 

  • Springer, C. J., Antoniw, P., Bagshawe, K. D., Searle, F., Bisset, G. M. F., and Jarman, M., 1990, Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2, J. Med. Chem. 33:677–681.

    Article  PubMed  CAS  Google Scholar 

  • Springer, C. J., Bagshawe, K. D., Sharma, S. K., Searle, F., Boden, J. A., Antoniw, P., Burke, P. J., Rogers, G. T., Sherwood, R. F., and Melton, R. G., 1991, Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds, Eur. J. Cancer 27:1361–1366.

    Article  PubMed  CAS  Google Scholar 

  • Springer, C. J., Dowell, R., Burke, P. J., Hadley, E., Davies, D. H., Blakey, D. C., Melton, R. G., and Niculescu-Duvaz, I., 1995, Optimisation of alkylating agent prodrugs derived from phenol and aniline mustards: A new clinical candidate prodrug (ZD2767) for ADEPT, J. Med. Chem. 38:5051–5065.

    Article  PubMed  CAS  Google Scholar 

  • Springer, C. J., Bavetsias, V., Jackman, A. L., Boyle, E. T., Marshall, D., Pedley, R. B., Bisset, G. M. F., 1996, Prodrugs of thymidylate synthase inhibitors: Potential for antibody directed enzyme pro-drug therapy (ADEPT), Anticancer Drug Des. 11:625–636.

    PubMed  CAS  Google Scholar 

  • Sunters, A., Baer, J., and Bagshawe, K. D., 1991, Cytotoxicity and activation of CB1954 in a human tumour cell line, Biochem. Pharm. 41:1293–1298.

    Article  PubMed  CAS  Google Scholar 

  • Svensson, H. P., Kadow, J. E, Vrudhula, V. M., Wallace, P. M., and Senter, P. D., 1992, Monoclonal antibody- 3-lactamase conjugates for the activation of a cephalosporin mustard prodrug, Bioconjugate Chem. 3:176–181.

    Article  CAS  Google Scholar 

  • Svensson, H. P., Vrudhula, V. M., Emswiler, J. E., MacMaster, J. F., Cosand, W. L., Senter, P. D., and Wallace, R. M., 1995, In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody 3-lactamase conjugates, Cancer Res. 55:2357–2365.

    PubMed  CAS  Google Scholar 

  • Tercel, M., Denny, W. A., and Wilson, W. R., 1996, A novel nitro-substituted seco-CI:Application as a reductively activated ADEPT prodrug, Bioorg. Medicinal Chem. Lett. 6:2741–2744.

    Article  CAS  Google Scholar 

  • Vitols, K. S., Haag-Zeino, B., Baer, T., Montejano, Y. D., and Huennekens, E M., 1995, Methotrexatea-phenylalanine: Optimisation of methotrexate prodrug for activation by carboxypeptidase A monoclonal antibody conjugate, Cancer Res. 55:478–481.

    PubMed  CAS  Google Scholar 

  • Vrudhula, V. M., Svensson, H. P., Kennedy, K. A., Senter, R. D., and Wallace, R M., 1993, Anti-tumour activities of a cephalosporin prodrug in combination with monoclonal antibody-ß-lactamase conjugates, Bioconjugate Chem. 4:334–340.

    Article  CAS  Google Scholar 

  • Vrudhula, V. M., Senter, R. D., Fischer, K. J., and Wallace, R M., 1993, Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin G amidase conjugate, J. Med. Chem. 36:919–923.

    Article  PubMed  CAS  Google Scholar 

  • Wallace, R M., and Senter, P. D., 1991, In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate, Bioconjugate Chem. 2:349–352.

    Article  CAS  Google Scholar 

  • Wallace, P. M., MacMaster, J. F., Smith, V. F., Kerr, D. E., Senter, R. D., and Cosand, W. L., 1994, Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine, Cancer Res. 54:2719–2723.

    PubMed  CAS  Google Scholar 

  • Wang, S. M., Chem, J. W., Yeh, M. Y., Ng, J. C., Tung, E., and Roffler, S. R., 1992, Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugate for cancer therapy, Cancer Res. 52:4484–4491.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Charing Cross Hospital, London, W6 8RP, UK

    P. J. Burke

Authors
  1. P. J. Burke
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Enzacta Ltd., Porton Down, Wiltshire, UK

    Roger G. Melton

  2. Imperial College School of Medicine, Charing Cross Campus, London, UK

    Richard J. Knox

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Burke, P.J. (1999). The Design and Synthesis of Prodrugs for Antibody-Directed Enzyme Prodrug Therapy (ADEPT). In: Melton, R.G., Knox, R.J. (eds) Enzyme-Prodrug Strategies for Cancer Therapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4823-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-4823-2_5

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7186-1

  • Online ISBN: 978-1-4615-4823-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation